

Goldman Sachs vs Blackstone
Large global investment bank and financial services firm vs World's largest alternative asset manager. Which is the better buy for your portfolio in November 2026? Plain-English answer below.
Goldman Sachs is the quintessential full-service investment bank, generating revenue across trading, advisory, and asset management within a regulated bank holding company structure, while Blackstone has become the world's largest alternative asset manager, building a fee-generating empire across private equity, real estate, credit, and infrastructure with minimal balance sheet risk. Both firms command prestige and compete fiercely for the same institutional capital and deal flow, but they've built their franchises on very different structural foundations. Goldman Sachs vs Blackstone gets at the defining question in financial services today: does the future belong to the balance sheet bank or the capital-light fee machine.
Goldman Sachs is the quintessential full-service investment bank, generating revenue across trading, advisory, and asset management within a regulated bank holding company structure, while Blackstone ...
Why It’s Moving

Goldman Sachs Leads Record $44B SpaceX Financing Amid Sector-Wide Bearish Signals
- Goldman Sachs and Apollo priced approximately $44 billion in senior and subordinated notes to fund GPU purchases for SpaceX, marking the largest GPU financing to date.
- Analysts have flagged a roughly 24% selloff from the stock's 52-week high, with some citing a need for a lower entry point due to volatile trading revenue exposure.
- The wider U.S. banking sector is flashing bearish technical signals, with the KBW Bank Index approaching a potential death cross that could pressure individual bank stocks.

Blackstone Deploys $2.25 Billion in Life Sciences Funding Amidst Major Infrastructure and Real Estate Moves
- Blackstone Life Sciences announced a $750 million funding agreement to support Johnson & Johnson’s Phase 3 clinical development of OLN324, an investigational therapy for retinal vascular diseases.
- The firm secured a separate deal to provide up to $1.5 billion through 2028 to Pfizer for the development of berobenatide, an experimental monthly obesity treatment acquired via Metsera.
- A Blackstone-backed transmission developer formed a partnership with OMERS to pursue the Toronto Third Line electricity procurement, reinforcing the firm's presence in critical energy infrastructure.

Goldman Sachs Leads Record $44B SpaceX Financing Amid Sector-Wide Bearish Signals
- Goldman Sachs and Apollo priced approximately $44 billion in senior and subordinated notes to fund GPU purchases for SpaceX, marking the largest GPU financing to date.
- Analysts have flagged a roughly 24% selloff from the stock's 52-week high, with some citing a need for a lower entry point due to volatile trading revenue exposure.
- The wider U.S. banking sector is flashing bearish technical signals, with the KBW Bank Index approaching a potential death cross that could pressure individual bank stocks.

Blackstone Deploys $2.25 Billion in Life Sciences Funding Amidst Major Infrastructure and Real Estate Moves
- Blackstone Life Sciences announced a $750 million funding agreement to support Johnson & Johnson’s Phase 3 clinical development of OLN324, an investigational therapy for retinal vascular diseases.
- The firm secured a separate deal to provide up to $1.5 billion through 2028 to Pfizer for the development of berobenatide, an experimental monthly obesity treatment acquired via Metsera.
- A Blackstone-backed transmission developer formed a partnership with OMERS to pursue the Toronto Third Line electricity procurement, reinforcing the firm's presence in critical energy infrastructure.
Investment Analysis
Pros
- Goldman Sachs leads the 2025 global mergers-and-acquisitions activity with $1.05 trillion in deals, demonstrating strong deal-making leadership and deal flow.
- The firm benefits from diversified operations spanning investment banking, asset management, and trading, supporting earnings stability across market cycles.
- Goldman Sachs has a history of accelerating earnings growth, underscoring effective execution in its core businesses and operational efficiency.
Considerations
- Goldman Sachs faces cyclical risks tied to market volatility and economic fluctuations impacting investment banking and trading revenues.
- Despite strong deal activity, rising regulatory scrutiny and compliance costs may pressure profit margins in the medium term.
- The firm's valuation is relatively high, which could limit upside potential if earnings growth slows or market conditions deteriorate.
Pros
- Blackstone expects accelerating management fee growth potentially exceeding 10% annually in 2025 and 2026, driven by fee holidays ending and new funds activation.
- The company demonstrates strength in its core private equity segment with anticipated acceleration in capital velocity and realizations boosting earnings.
- Blackstone remains an active net buyer in real estate, positioning for growth along with diversified segments including credit, insurance, and hedge funds.
Considerations
- Blackstone's stock trades at a premium valuation with an adjusted P/E ratio around 57, indicating high growth expectations that may be challenging to meet.
- Recent slight negative revisions to 2025 earnings per share suggest some near-term growth risks despite optimistic management outlooks.
- The firm's market share is moderate relative to some competitors, potentially indicating challenges in scaling certain business lines amid competitive pressures.
Goldman Sachs (GS) Next Earnings Date
Goldman Sachs has a confirmed upcoming earnings report scheduled for January 19, 2027, at 07:30 AM EST before the market opens. This release will cover the fourth quarter of fiscal year 2026, following their most recent report on October 13, 2026. The timing aligns with the company's historical pattern of reporting approximately three months after the previous quarter's close.
Blackstone (BX) Next Earnings Date
The next earnings date for Blackstone (BX) has not been confirmed yet. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous release, the next report is expected in January 2027. This upcoming announcement will cover the fourth quarter of fiscal year 2026.
Goldman Sachs (GS) Next Earnings Date
Goldman Sachs has a confirmed upcoming earnings report scheduled for January 19, 2027, at 07:30 AM EST before the market opens. This release will cover the fourth quarter of fiscal year 2026, following their most recent report on October 13, 2026. The timing aligns with the company's historical pattern of reporting approximately three months after the previous quarter's close.
Blackstone (BX) Next Earnings Date
The next earnings date for Blackstone (BX) has not been confirmed yet. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous release, the next report is expected in January 2027. This upcoming announcement will cover the fourth quarter of fiscal year 2026.
Buy GS or BX in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


